Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1‐year treatment in non‐diabetic subjects with insulin resistance

References

• Ferrannini E., Buzzigoli G., Bonadonna R., Giorico M. A., Oleggini M., Graziadei L., et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–357
   PubMed Web of Science ®Google Scholar
• Pollare T., Lithell H., Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39: 167–174
   PubMed Web of Science ®Google Scholar
• Nilsson P., Lind L., Andersson P‐E., Hänni A., Berne C., Baron J., et al. On the use of ambulatory blood pressure recordings and insulin sensitivity in support of the insulin‐hypertension hypothesis. J Hypertens 1994; 12: 965–969
   PubMed Web of Science ®Google Scholar
• Nilsson P., Lindholm L., Scherstén B. Lifestyle changes improves insulin resistance in hyperinsulinemic subjects. A one‐year intervention study of hypertensives and normotensives in Dalby. J Hypertens 1992; 10: 1071–1078
   PubMed Web of Science ®Google Scholar
• Dengel D. R., Hagberg J. M., Pratley R. E., Rogus E. M., Goldberg A. P. Improvements in blood pressure, glucose metabolism, and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middle‐aged men. Metabolism 1998; 47: 1075–1082
   PubMed Web of Science ®Google Scholar
• Lithell H. O. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203–209
   PubMed Web of Science ®Google Scholar
• Mancia G., Grassi G., Zanchetti A. New‐onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10
   PubMed Web of Science ®Google Scholar
• Qayyum R., Adomaityte J. A meta‐analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens (Greenwich) 2006; 8: 19–28
   PubMedGoogle Scholar
• St John Sutton M., Rendell M., Dandona P., Dole J. F., Murphy K., Patwardhan R., et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058–2064
   PubMed Web of Science ®Google Scholar
• Tan M. H., Johns D., Strand J., Halse J., Madsbad S., Eriksson J. W., et al. GLAC Study Group. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet Med 2004; 21: 859–866
   PubMed Web of Science ®Google Scholar
• Negro R., Mangieri T., Dazzi D., Pezzarossa A., Hassan H. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract 2005; 70: 20–25
   PubMed Web of Science ®Google Scholar
• Rajagopalan R., Iyer S., Khan M. Effect of pioglitazone on metabolic syndrome risk factors: Results of double‐blind, multicenter, randomized clinical trials. Curr Med Res Opin 2005; 21: 163–172
   PubMed Web of Science ®Google Scholar
• Yki‐Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106–1118
   PubMed Web of Science ®Google Scholar
• Sarafidis P. A., Lasaridis A. N., Nilsson P. M., Hitoglou‐Makedou A. D., Pliakos C. I., Kiriakos A., et al. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 2004; 22: 1769–1777
   PubMed Web of Science ®Google Scholar
• Sarafidis P., Nilsson P. M. The effects of thiazolidinedione compounds on blood pressure levels – A systematic review. Blood Press 2006; 15: 135–150
   PubMed Web of Science ®Google Scholar
• Hedblad B., Nilsson P. M., Zambanini A., Berglund G. Rosiglitazone reduces carotid intima‐media thickness progression over 1 year in patients with type 2 diabetes but not in non‐diabetic people who have insulin resistance alone. J Internal Med 2007; 261: 293–305
   Google Scholar
• Hedblad B., Nilsson P., Janzon L., Berglund G. Relation between insulin resistance and carotid intima‐media thickness and stenosis in non‐diabetic subjects. Results from a cross‐sectional study in Malmö, Sweden. Diabetic Med 2000; 17: 299–307
   PubMed Web of Science ®Google Scholar
• Hedblad B., Wikstrand J., Janzon L., Wedel H., Berglund G. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima‐media thickness. Main results from the Beta‐blocker Cholesterol‐lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721–1726
   PubMed Web of Science ®Google Scholar
• Matthews D. R., Hosker J. P., Rudenski A. S., Naylor B. A., Treacher D. F., Turner R. C. Homeostasis model assessment: Insulin resistance and beta‐cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419
   PubMed Web of Science ®Google Scholar
• Balkau B., Charles M. A., for the European Group for the Study of Insulin Resistance (EGIR). Comment on the provisional report from the WHO consultation. Diabet Med 1999; 16: 442–443
   PubMed Web of Science ®Google Scholar
• Turnbull F., Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood‐pressure‐lowering regimens on major cardiovascular events: Results of prospectively‐designed overviews of randomised trials. Lancet 2003; 362: 1527–1535
   PubMed Web of Science ®Google Scholar
• Mancia G., Parati G. The role of blood pressure variability in end‐organ damage. J Hypertens 2003; 21 Suppl 6: S17–S23
   Web of Science ®Google Scholar
• Verdecchia P. Prognostic value of ambulatory blood pressure. Current evidence and clinical implications. Hypertension 2000; 35: 844–851
   PubMed Web of Science ®Google Scholar
• DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006; 368: 1096–1105
   PubMed Web of Science ®Google Scholar
• Dormandy J. A., Charbonnel B., Eckland D. J. A., Erdmann E., Massi‐Benedetti M., Moules I. K., , on behalf of the PROactive investigators, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005; 366: 1279–1289
   PubMed Web of Science ®Google Scholar
• Bakris G. L., Ruilope L. M., McMorn S. O., Weston W. M., Heise M. A., Freed M. I., et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006; 24: 2047–2055
   PubMed Web of Science ®Google Scholar
• Yosefy C., Magen E., Kiselevich A., Priluk R., London D., Volchek L., et al. Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004; 44: 215–222
   PubMed Web of Science ®Google Scholar
• Pistrosch F., Passauer J., Fischer S., Fuecker K., Hanefeld M., Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27: 484–90
   PubMed Web of Science ®Google Scholar
• Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–575
   PubMed Web of Science ®Google Scholar
• Boger R. H., Bode‐Boger S. M., Szuba A., Tsao P. S., Chan J. R., Tangphao O., et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842–1847
   PubMed Web of Science ®Google Scholar
• Stuhlinger M. C., Abbasi F., Chu J. W., Lamendola C., McLaughlin T. L., Cooke J. P., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420–1426
   PubMed Web of Science ®Google Scholar
• Shargorodsky M., Wainstein J., Gavish D., Leibovitz E., Matas Z., Zimlichman R. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in subjects with type 2 diabetes mellitus. Am J Hypertens 2003;16:617–622. Erratum in: Am J Hypertens 2003; 16: 84
   Web of Science ®Google Scholar
• Bennett S. M., Agrawal A., Elasha H., Heise M., Jones N. P., Walker M., et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med 2004; 21: 415–422
   PubMed Web of Science ®Google Scholar
• Natali A., Baldeweg S., Toschi E., Capaldo B., Barbaro D., Gastaldelli A., et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004; 27: 1349–1357
   PubMed Web of Science ®Google Scholar